

Expanded View Figures

Figure EV1. Polyalanine stretches regulate UBA6-USE1 interaction and ubiquitin transfer.

(A) FLAG-WT USE1, FLAG-USE1 Δ PolyAla, FLAG-USE1 C188A, and FLAG-USE1 Δ LB were co-expressed with HA-Ub in HEK293T cells. Cell lysates were incubated with or without β mercaptoethanol (β ME) and analyzed for ubiquitin loading. Results are normalized to control WT USE1. n = 4 biological replicates. (B) A representative blot for time-dependent in vitro ubiquitin loading of WT and Δ PolyAla USE1 by UBA6 (quantification is presented in Fig. 1C). (C) WT and Δ PolyAla KO cells were treated with the cross-linker formaldehyde and cell lysates were immunoprecipitated with anti-USE1 or control IgG antibodies. Immunocomplexes were analyzed with anti-USE1 and anti-UBA6 antibodies. (D) FLAG-WT USE1, empty GFP and GFP-polyAla (19Ala) constructs were transfected into HEK293T cells. Cell lysates were immunoprecipitated with anti-UBA6 and anti-GFP antibodies. The bound USE1/UBA6 ratio is shown. n = 3 biological replicates. Data information: Data points in (A, D) represent mean ± s.e.m. *P* values were calculated by one-way ANOVA Tukey's test (A) or paired 2-tailed *t* test (D). ***P*< 0.01, *****P*< 0.0001. Source data are available online for this figure.



Figure EV2. Biophysical analysis of the interaction between a polyalanine peptide and the SCCH domains of the canonical E1 ubiquitin-like activating enzymes.

(A) AlphaFold models of UBA6 and UBA7 and the crystal structures of UBA1, UBA2 and UBA3 are shown. The structures were aligned and electrostatic potential was calculated as described in the methods. The yellow arrows indicate the location of the groove within the SCCH domains. UBA6, UBA1 and UBA7 form an extended lobe within the SCCH, which is missing in UBA2 and UBA3. The groove in UBA7 is covered and do not exist in UBA2 and UBA3. The grooves in UBA1 and UBA6 are highly similar in terms of structure but present significantly different electro potential surfaces. The gradient from negative (red) to positive (blue) charge is shown. The figure was prepared by PyMol. (B) Microscale thermophoresis interaction analysis of cy5-7Ala-peptide against UBA6 or UBA1 SCCH domain. The dose-response curve of cy5-7Ala-peptide titrated against increasing concentrations of the SCCH domain is presented. Results are mean ± s.e.m. n = 4 biological replicates, Two-way ANOVA, Sidak's test. ****P < 0.0001.



MG132 + + + +

Figure EV3. Cytoplasmic polyalanine-expanded disease proteins interact with UBA6 and decrease USE1 ubiquitin loading and E6AP polyubiquitination.

(A-D) HEK293T cells were transfected with the indicated constructs: (A) HA-mutant PHOX2B (+13Ala). (B) HA-mutant RUNX2 (+12Ala). (C) HA-mutant HOXD13 (+10Ala). (D) HA-mutant PABPN1 (+7 Ala). Endogenous UBA6 was immunoprecipitated from the nuclear fraction (Nuc, LaminB1 enriched) or the cytoplasmic (Cyt, GAPDH enriched) fraction (unrelated IgG was used as a control). The immunocomplexes were analyzed with anti-HA antibodies. (E) HEK293T cells were transfected with constructs expressing different polyalanine-expanded disease proteins (mutant PHOX2B, mutant RUNX2, mutant HOXD13, and mutant PABPN1) together with FLAG-USE1. Cell lysates were incubated without β mercaptoethanol and analyzed for ubiquitin loading. Results are mean ± s.e.m. normalized to control (empty vector, no disease protein). Paired 2-tailed t test. *n* = 3-6 biological replicates. (F) Control and UBA6-depleted HEK293T cells were transfected with HA-Ub, mutant PHOX2B or empty vector and incubated for the last 6 h with the proteasome inhibitor MG132 (10 µM). Endogenous E6AP was immunoprecipitated from cell lysates for ubiquitination analysis (unrelated IgG was used as a control). ns non-significant, **P* < 0.05, ***P* < 0.01.

2.0

1.5

1.0

0.5

0.0

E6AP / Actin

ns

WT 7A12 A12













30

10

0

Arc intensity (AU) 20 ns



*nctiern up as

WT 3 A12



Ε



Figure EV4. UBA6 overexpression affects E6AP and Arc levels in mutant PHOX2B transduced neurons.

(A-C) Mouse primary cortical neurons were transduced with lentiviral vectors expressing GFP-tagged WT PHOX2B or mutant PHOX2B (+7Ala or +13Ala). (A) Quantification of the association of GFP-PHOX2B with the nucleus (Pearson's coefficient) is presented as well as GFP-PHOX2B cytoplasmic intensity, related to Fig. 4C. (B) Analysis of E6AP and Arc levels in the WT and mutant PHOX2B-expressing neurons (n = 5 and n = 4 biological replicates, respectively). (C) Quantification of Arc intensity in the GFP-PHOX2B expressing neurons is presented (image scale bar 10 µm) as well as a blot showing Arc protein levels. Results represent the average values from neurons in different imaged fields. n = 20, n = 30 and n = 100 neurons analyzed for WT PHOX2B, mutant PHOX2B +7Ala and +13Ala, respectively. (D-F) The neurons were transduced with lentiviral vectors expressing GFP-WT PHOX2B, GFP-mutant PHOX2B (+13Ala) with or without lentiviruses encoding for mCherry-UBA6. (D), E6AP levels were analyzed in cell lysates. Results are normalized to WT PHOX2B. n = 4 biological replicates. (E, F) Quantification of Arc intensity in cycloheximidetreated GFP-PHOX2B expressing neurons that were positive or negative to mCherry. n = 110, n = 150 and n = 50 neuronal cell bodies analyzed for WT PHOX2B, mutant PHOX2B and mutant PHOX2B + UBA6, respectively. Inset shows mCherry signal. Scale bar 10 µm. AU arbitrary units. Data information: Data points in (A-D, F) represent mean ± s.e.m. *P* values were calculated by one-way ANOVA Tukey's test (A-D, F). $^{+}P < 0.05$, $^{+*}P < 0.01$, $^{+**+P} < 0.001$, ns non-significant.



Figure EV5. Patient-derived autonomic neurons showing cytoplasmic mislocalized soluble PHOX2B, and decreased Arc levels.

(A, B) Quantification of the association of endogenous PHOX2B with the nucleus (Pearson's coefficient) in autonomic neurons from control and CCHS patients. Quantification is shown also for PHOX2B cytoplasmic intensity. Total number of neurons analyzed was 160 for 103iCTR 20/20, 350 for 102iCCHS 20/25, 380 for 105iCTR 20/20 and 550 for 104iCCHS 20/27. The results represent additional analysis from the same neurons analyzed in Fig. 5B. (C) Autonomic neurons from control and CCHS patients were analyzed for the levels of PHOX2B in the soluble and sarkosyl-insoluble fractions. (D) iPSC-derived human autonomic neurons from control and CCHS patients were labeled by nuclear staining (colored blue, abnormal nuclear morphology marked with arrows), and for endogenous PHOX2B (colored green) and endogenous UBA6 (colored red). Images indicate events of severe cytoplasmic mislocalization of PHOX2B (marked with arrows). Scale bar 10 µm. (E, F) Immunostaining of Arc (colored green) and TUBβ3 (colored red) in autonomic neurons from control and CCHS patients. Scale bar 20µm. For quantification, Arc intensity was normalized to TUBβ3 in different image fields. Number of neurons analyzed 105iCTR 20/20 n = 105, 102iCCHS 20/25 n = 220, 104iCCHS 20/27 n = 166. (G) Analysis of Arc levels in the autonomic neurons from control and CCHS patients. (I) Quantification of the abundance of UBA6 cDNA in CCHS patient-derived neurons. Results are normalized to control line. n = 3 biological replicates. (H) Analysis of shank3 levels in mouse primary cortical neurons and in autonomic neurons from control and CCHS patients. (I) Quantification of the abundance of UBA6 cDNA in CCHS patient-derived neurons. Representative images are presented for mCherry (colored red) and TUBβ3 staining (colored blue) in the patient neurons (scale bar 20 µm). For quantification, the percentage of mCherry coverage from the TUBβ3 staining was calculated in different image fields (n = 80 neurons). Data information: Data points in (**A**, **B**, **F**, **G**, **I**) repres